Therapeutic Response

t(KMT2A;v) status confers therapeutic sensitivity to Revumenib in patients with Acute Leukemias of Ambiguous Lineage.

Statements

Source and description
Revuforj (revumenib) [package insert]. FDA. The U.S. Food and Drug Administration (FDA) granted approval to revumenib for the treatment of adult and pediatric patients 1 year and older with relapsed or refractory acute leukemia with a lysine methyltransferase 2A gene (KMT2A) translocation.